Antiviral strategies based on lethal mutagenesis and error threshold

Current Topics in Microbiology and Immunology

Volumn 392, Issue , 2016, Pages 323-339

  Perales, Celia ^a,b,c   Domingo, Esteban ^a,b  

^a CSIC   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FAVIPIRAVIR; NUCLEOSIDE DERIVATIVE; ANTIVIRUS AGENT;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; COMMUNITY STRUCTURE; DISEASE CONTROL; DRUG DESIGN; DRUG EFFICACY; ERROR CATASTROPHE; ERROR THRESHOLD; GENETIC VARIABILITY; HEPATITIS C VIRUS; HUMAN; LETHAL DEFECTION; LETHAL MUTAGENESIS; MOLECULAR BIOLOGY; MOLECULAR CLONING; MUTAGENESIS; MUTATION RATE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; QUASISPECIES DYNAMICS; QUASISPECIES THEORY; REFERENCE VALUE; REPLICON; THEORY; VIRAL FITNESS; VIRAL PHENOMENA AND FUNCTIONS; VIRUS CELL INTERACTION; VIRUS DISEASE CONTROL; VIRUS GENOME; VIRUS LOAD; VIRUS REPLICATION; VIRUS SURVIVAL; VIRUS TITRATION; VIRUS VIRULENCE; ANIMAL; DRUG EFFECTS; GENETICS; VIROLOGY; VIRUS; VIRUS DISEASES;

ANIMALS; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HUMANS; MUTAGENESIS; VIRUS DISEASES; VIRUS REPLICATION; VIRUSES;

EID: 84958086068     PISSN: 0070217X     EISSN: 21969965     Source Type: Book Series    
DOI: 10.1007/82_2015_459     Document Type: Chapter

References (64)

1. Agudo R, Arias A, Pariente N et al (2008) Molecular characterization of a dual inhibitory and mutagenic activity of 5-fluorouridine triphosphate on viral RNA synthesis. Implications for lethal mutagenesis. J Mol Biol 382:652–666
2. Anderson JP, Daifuku R, Loeb LA (2004) Viral error catastrophe by mutagenic nucleosides. Annu Rev Microbiol 58:183–205
3. Arias A, Isabel de Avila A, Sanz-Ramos M et al (2013) Molecular dissection of a viral quasispecies under mutagenic treatment: positive correlation between fitness loss and mutational load. J Gen Virol 94:817–830
4. Arias A, Thorne L, Goodfellow I (2014) Favipiravir elicits antiviral mutagenesis during virus replication in vivo. eLife 3:e03679
5. Baranovich T, Wong SS, Armstrong J et al (2013) T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J Virol 87:3741–3751
6. Cale EM, Hraber P, Giorgi EE et al (2011) Epitope-specific CD8 + T lymphocytes cross-recognize mutant simian immunodeficiency virus (SIV) sequences but fail to contain very early evolution and eventual fixation of epitope escape mutations during SIV infection. J Virol 85:3746–3757
7. Crotty S, Cameron CE, Andino R (2001) RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci USA 98:6895–6900
8. Cupples CG, Miller JH (1989) A set of lacZ mutations in Escherichia coli that allow rapid detection of each of the six base substitutions. Proc Natl Acad Sci USA 86:5345–5349
9. Dapp MJ, Patterson SE, Mansky LM (2013) Back to the future: revisiting HIV-1 lethal mutagenesis. Trends Microbiol 21:56–62
10. De Clercq E (2015) Ebola virus (EBOV) infection: therapeutic strategies. Biochem Pharmacol 93:1–10
11. Domingo E (2000) Viruses at the edge of adaptation. Virology 270:251–253
12. Domingo E, Brun A, Núñez JI et al (2006) Genomics of Viruses. In: Hacker J, Dobrindt U (eds) Pathogenomics: genome analysis of pathogenic microbes. Wiley-VCH Verlag GmbH & Co., KGaA, Weinheim, pp 369–388
13. Domingo E, Schuster P (2016) What is a quasispecies? Historical origins and current scope. Curr Top Microbiol Immunol doi:10.1007/82_2015_453
14. Domingo E, Sheldon J, Perales C (2012) Viral quasispecies evolution. Microbiol Mol Biol Rev 76:159–216
15. Domingo E (ed) (2005) Virus entry into error catastrophe as a new antiviral strategy. Virus Res 107:115–228
16. Drake JW, Holland JJ (1999) Mutation rates among RNA viruses. Proc Natl Acad Sci USA 96:13910–13913
17. Eigen M (2013) From strange simplicity to complex amiliarity. Oxford University Press, Oxford
18. Fischer W, Ganusov VV, Giorgi EE et al (2010) Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. PLoS ONE 5:e12303
19. Gerold G, Pietschmann T (2014) The HCV life cycle: in vitro tissue culture systems and therapeutic targets. Dig Dis 32:525–537
20. González-López C, Arias A, Pariente N et al (2004) Preextinction viral RNA can interfere with infectivity. J Virol 78:3319–3324
21. González-López C, Gómez-Mariano G, Escarmís C et al (2005) Invariant aphthovirus consensus nucleotide sequence in the transition to error catastrophe. Inf Genet Evol 5:366–374
22. Graci JD, Cameron CE (2008) Therapeutically targeting RNA viruses via lethal mutagenesis. Future Virol 3:553–566
23. Grande-Pérez A, Gómez-Mariano G, Lowenstein PR et al (2005a) Mutagenesis-induced, large fitness variations with an invariant arenavirus consensus genomic nucleotide sequence. J Virol 79:10451–10459
24. Grande-Pérez A, Lazaro E, Lowenstein P et al (2005b) Suppression of viral infectivity through lethal defection. Proc Natl Acad Sci USA 102:4448–4452
25. Grande-Perez, A, Martin V, Moreno H, de la torre JC (2016) Arenavirus quasispecies and their biological implications. Current Topics in Microbiol and immunol. doi:10.1007/82_2015_468
26. Holland JJ, Spindler K, Horodyski F et al (1982) Rapid evolution of RNA genomes. Science 215:1577–1585
27. Holland JJ, Domingo E, de la Torre JC et al (1990) Mutation frequencies at defined single codon sites in vesicular stomatitis virus and poliovirus can be increased only slightly by chemical mutagenesis. J Virol 64:3960–3962
28. Iranzo J, Perales C, Domingo E et al (2011) Tempo and mode of inhibitor-mutagen antiviral therapies: a multidisciplinary approach. Proc Natl Acad Sci USA 108:16008–16013
29. Li YP, Ramirez S, Mikkelsen L et al (2015) Efficient infectious cell culture systems of the hepatitis C virus (HCV) prototype strains HCV-1 and H77. J Virol 89:811–823
30. Lindenbach BD, Evans MJ, Syder AJ et al (2005) Complete replication of hepatitis C virus in cell culture. Science 309:623–626
31. Loeb LA, Essigmann JM, Kazazi F et al (1999) Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc Natl Acad Sci USA 96:1492–1497
32. Lucas-Hourani M, Dauzonne D, Jorda P et al (2013) Inhibition of pyrimidine biosynthesis pathway suppresses viral growth through innate immunity. PLoS Pathog 9:e1003678
33. Moreno H, Grande-Perez A, Domingo E et al (2012) Arenaviruses and lethal mutagenesis. Prospects for new ribavirin-based interventions. Viruses 4:2786–2805
34. Mullins JI, Heath L, Hughes JP et al (2011) Mutation of HIV-1 genomes in a clinical population treated with the mutagenic nucleoside KP1461. PLoS ONE 6:e15135
35. Nájera I, Holguín A, Quiñones-Mateu ME et al (1995) Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol 69:23–31
36. Nijhuis M, van Maarseveen NM, Boucher CA (2009) Antiviral resistance and impact on viral replication capacity: evolution of viruses under antiviral pressure occurs in three phases. Handb Exp Pharmacol 299–320
37. Oestereich L, Ludtke A, Wurr S et al (2014) Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res 105:17–21
38. Orgel LE (1963) The maintenance of the accuracy of protein synthesis and its relevance to ageing. Proc Natl Acad Sci USA 49:517–521
39. Orgel LE (1973) Ageing of clones of mammalian cells. Nature 243:441–445
40. Ortega-Prieto AM, Sheldon J, Grande-Perez A et al (2013) Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis. PLoS ONE 8:e71039
41. Ortiz-Riano E, Ngo N, Devito S et al (2014) Inhibition of arenavirus by A3, a pyrimidine biosynthesis inhibitor. J Virol 88:878–889
42. Padmanabhan P, Dixit NM (2016) Models of viral population dynamics. Curr Top Microbiol Immunol. doi:10.1007/82_2015_458
43. Pariente N, Sierra S, Lowenstein PR et al (2001) Efficient virus extinction by combinations of a mutagen and antiviral inhibitors. J Virol 75:9723–9730
44. Pariente N, Airaksinen A, Domingo E (2003) Mutagenesis versus inhibition in the efficiency of extinction of foot-and-mouth disease virus. J Virol 77:7131–7138
45. Perales C, Mateo R, Mateu MG et al (2007) Insights into RNA virus mutant spectrum and lethal mutagenesis events: replicative interference and complementation by multiple point mutants. J Mol Biol 369:985–1000
46. Perales C, Agudo R, Tejero H et al (2009) Potential benefits of sequential inhibitor-mutagen treatments of RNA virus infections. PLoS Pathog 5:e1000658
47. Perales C, Agudo R, Manrubia SC et al (2011a) Influence of mutagenesis and viral load on the sustained low-level replication of an RNA virus. J Mol Biol 407:60–78
48. Perales C, Henry M, Domingo E et al (2011b) Lethal mutagenesis of foot-and-mouth disease virus involves shifts in sequence space. J Virol 85:12227–12240
49. Perales C, Iranzo J, Manrubia SC et al (2012) The impact of quasispecies dynamics on the use of therapeutics. Trends Microbiol 20:595–603
50. Perales C, Beach NM, Gallego I et al (2013) Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype. J Virol 87:7593–7607
51. Perales C, Beach NM, Sheldon J et al (2014) Molecular basis of interferon resistance in hepatitis C virus. Curr Opin Virol 8C:38–44
52. Perales C, Iranzo J, Sheldon J et al (2015) Impact of fitness and inhibition in the response of hepatitis C to lethal mutagenesis (Manuscript in preparation)
53. Richman DD (1996) Antiviral drug resistance. Wiley, New York
54. Ruiz-Jarabo CM, Ly C, Domingo E et al (2003) Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). Virology 308:37–47
55. Schuster P (2016) Quasispecies on fitness landscapes. Curr Top Microbiol Immunol. doi:10.1007/82_2015_469
56. Sheldon J, Beach NM, Moreno E et al (2014) Increased replicative fitness can lead to decreased drug sensitivity of hepatitis C virus. J Virol 88:12098–12111
57. Sierra S, Dávila M, Lowenstein PR et al (2000) Response of foot-and-mouth disease virus to increased mutagenesis. Influence of viral load and fitness in loss of infectivity. J Virol 74:8316–8323
58. Smither SJ, Eastaugh LS, Steward JA et al (2014) Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Res 104:153–155
59. Steinmeyer SH, Wilke CO (2009) Lethal mutagenesis in a structured environment. J Theor Biol 261:67–73
60. Tapia N, Fernandez G, Parera M et al (2005) Combination of a mutagenic agent with a reverse transcriptase inhibitor results in systematic inhibition of HIV-1 infection. Virology 338:1–8
61. Tejero H, Montero F, Nuño JC (2016) Theories of lethal mutagenesis: from error catastrophe to lethal defection. Curr top Microbiol immunol. doi:10.1007/82_2015_463
62. Tsibris AM, Korber B, Arnaout R et al (2009) Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS ONE 4:e5683
63. Wakita T, Pietschmann T, Kato T et al (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11:791–796
64. Zhong J, Gastaminza P, Cheng G et al (2005) Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 102:9294–9299